# A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT01248923** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 55 (actual)

## Conditions studied

- Multiple Myeloma, Plasma Cell Leukemia

## Interventions

- **DRUG:** ARRY-520, KSP(Eg5) inhibitor; intravenous
- **DRUG:** Bortezomib, proteasome inhibitor; intravenous or subcutaneous
- **DRUG:** Dexamethasone, steroid; oral
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- **DRUG:** ARRY-520, KSP(Eg5) inhibitor; intravenous
- **DRUG:** Bortezomib, proteasome inhibitor; intravenous or subcutaneous
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

## Key facts

- **NCT ID:** NCT01248923
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248923, "A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01248923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*